Development of a Theranostic Convergence Bioradiopharmaceutical for Immuno-PET Based Radioimmunotherapy of L1CAM in Cholangiocarcinoma Model.

In Ho SongMun Sik JeongHyo Jeong HongJong Il ShinYong Serk ParkSang-Keun WooByung Seok MoonKwang Il KimYong Jin LeeJoo Hyun Kang

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Anti-L1CAM immuno-PET imaging using 64Cu-cA10-A3 could be translated into the clinic for characterizing the pharmacokinetics and selecting appropriate patients for radioimmunotherapy. Radioimmunotherapy using 177Lu-cA10-A3 may provide survival benefit in L1CAM-expressing cholangiocarcinoma tumor. Theranostic convergence bioradiopharmaceutical strategy would be applied as imaging biomarker-based personalized medicine in L1CAM-expressing patients with cholangiocarcinoma.

Keyphrases

pet imaging
end stage renal disease
photodynamic therapy
ejection fraction
newly diagnosed
fluorescence imaging
positron emission tomography
chronic kidney disease
primary care
patient reported outcomes
patient reported
free survival
metal organic framework